Press release
Primary Ovarian Insufficiency Market Size Forecasted To Achieve 1.73 Billion By 2029 With Steady Growth
Primary Ovarian Insufficiency Market
What Is the Primary Ovarian Insufficiency Market Size and Projected Growth Rate?
The market size for primary ovarian insufficiency has seen a swift expansion in the past few years. The market size, which was $1.07 billion in 2024, is projected to reach $1.18 billion in 2025, at a compound annual growth rate (CAGR) of 10.1%. The growth recorded in the recent past can be linked to factors like the escalating incidences of autoimmune diseases, heightened stress levels, growing number of genetic mutations, an increase in women opting for delayed childbirth, and a rise in endocrine disorder occurrences.
Future years are projected to witness a swift expansion of the primary ovarian insufficiency market, with its predicted size reaching $1.73 billion in 2029 with a compound annual growth rate (CAGR) of 10.0%. This anticipated growth throughout the forecast period can be traced back to the rising adoption of assisted reproductive technologies, increased preference for fertility preservation alternatives, mounting emphasis on personalized medicine, and a growing attraction towards hormonal therapies as well as the escalating utilization of fertility preservation methods. The market forecast includes ongoing trends such as advancements in diagnostic technology, the incorporation of genetic testing, tech advancements in fertility preservation, breakthroughs in non-hormonal therapies, and the innovation of early detection biomarkers.
Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/customise?id=24387&type=smp
What Are the Major Segments in the Primary Ovarian Insufficiency Market?
The primary ovarian insufficiency market covered in this report is segmented -
1) By Type: Hormone Replacement Therapy (HRT), Calcium and Vitamin D Supplements, In Vitro Fertilization (IVF), Stem Cell Therapy, Other Types
2) By Diagnosis Method: Blood Tests, Ultrasound Imaging, Genetic Testing
3) By Application: Less Than 20 Years Old, 20 To 30 Years Old, 30 To 45 Years Old, 45 Years Old And Older
4) By End-Users: Hospitals And Clinics, Specialty Fertility Centers
Subsegments:
1) By Hormone Replacement Therapy: Estrogen Therapy, Estrogen-Progestin Therapy, Transdermal Patches, Vaginal Estrogen Products, Oral Hormone Therapy
2) By Calcium And Vitamin D Supplements: Calcium Carbonate, Calcium Citrate, Vitamin D2 (Ergocalciferol), Vitamin D3 (Cholecalciferol), Combined Calcium + Vitamin D Formulations
3) By In Vitro Fertilization: Conventional In Vitro Fertilization, Intracytoplasmic Sperm Injection (ICSI), Egg Donation In Vitro Fertilization, Embryo Freezing And Transfer, Preimplantation Genetic Testing (PGT)
4) By Stem Cell Therapy: Autologous Stem Cell Therapy, Allogeneic Stem Cell Therapy, Mesenchymal Stem Cell (MSC) Therapy, Ovarian Stem Cell Transplantation
5) By Other Types: Psychological Counseling And Support Therapies, Assisted Reproductive Technologies (other than IVF), Immunomodulatory Therapies, Lifestyle And Dietary Interventions
Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24387&type=smp
What Are The Driving Primary Ovarian Insufficiency Market Evolution?
The rise in autoimmune disorders is anticipated to fuel the expansion of the primary ovarian insufficiency market. Autoimmune disorders are diseases in which the body's immune system erroneously attacks and destroys its own healthy cells and tissues. This surge in autoimmune disorders is primarily attributed to genetic predisposition, where certain inherited genes increase vulnerability to immune system malfunctions. Primary ovarian insufficiency (POI) contributes to a deeper comprehension of autoimmune disorders by illustrating how hormonal imbalance and immune system dysregulation interplay, raising the chances of autoimmune diseases in the affected population. For example, Versorgungsatlas.de, a German organization, stated in November 2024, that in 2022, out of 73,241,305 insured individuals, 6,304,340 were diagnosed with at least one autoimmune disease. This accounted for a crude prevalence rate of 8.61%. Consequently, the escalating prevalence of autoimmune disorders is propelling the growth of the primary ovarian insufficiency market.
Which Firms Dominate The Primary Ovarian Insufficiency Market Segments?
Major companies operating in the primary ovarian insufficiency market are Mayo Clinic, Johns Hopkins Medicine, Baptist Health, Ferring Pharmaceuticals A/S, The Kingsley Natural Health Clinic, PreventionGenetics LLC, The Fertility Partnership (TFP) UK, Celmatix Inc., European Society of Human Reproduction and Embryology (ESHRE), Endocrine Society, IVIRMA Global, American Society for Reproductive Medicine (ASRM), TCM Healthcare (UK) Ltd., Bioscience Institute S.p.A., Sparsh Diagnostics Pvt. Ltd., Welling Homeopathy Clinics Pvt. Ltd., Bristol Menopause Clinic, Indira IVF Hospital Private Limited, Lawley Pharmaceuticals Pty. Ltd., OvaScience Inc.
What Are the Major Trends Shaping the Primary Ovarian Insufficiency Market?
The key players in the market for primary ovarian insufficiency are focusing on the development of innovative treatments like allogenic exosomal therapy to improve fertility and restore ovarian functionality. This therapy utilizes exosomes - extracellular vesicles which are derived from stem cells of a donor - to send signals for regeneration that promote tissue repair and reinstate ovarian functionality for patients afflicted with primary ovarian insufficiency. As an example, in October 2022, the FDA gave the green light to Vitti Labs LLC, a biotech company from the US, for the deployment of EV-Pure to treat primary ovarian insufficiency. This leverages the anti-inflammatory, regenerative, and immunomodulatory attributes of exosomes derived from mesenchymal stromal cells to reestablish fertility and ovarian functionality. This is a ready-to-use, cell-free therapy that negates the risks often associated with cell-based treatments, such as immune rejection or malignant transformation, and simultaneously delivers bioactive molecules geared towards promoting tissue repair and homeostasis.
Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/primary-ovarian-insufficiency-global-market-report
Which Is The Largest Region In The Primary Ovarian Insufficiency Market?
North America was the largest region in the primary ovarian insufficiency market in 2024. The regions covered in the primary ovarian insufficiency market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Primary Ovarian Insufficiency Market?
2. What is the CAGR expected in the Primary Ovarian Insufficiency Market?
3. What Are the Key Innovations Transforming the Primary Ovarian Insufficiency Industry?
4. Which Region Is Leading the Primary Ovarian Insufficiency Market?
Why This Report Matters:
Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.
Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.
Efficient Research: Quickly identify market growth, leading players, and major segments.
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Primary Ovarian Insufficiency Market Size Forecasted To Achieve 1.73 Billion By 2029 With Steady Growth here
News-ID: 4060924 • Views: …
More Releases from The Business Research Company
Segment Evaluation and Major Growth Areas in the Personalized Testing and Supple …
The personalized testing and supplements sector is gaining remarkable traction, driven by advancements in technology and a rising consumer focus on tailored health solutions. As more individuals seek customized wellness options, this market is set to experience substantial expansion in the coming years. Here's an in-depth look at its current valuation, key players, significant trends, and the main market segments shaping its future.
Market Valuation and Expansion Forecast for Personalized Testing…
Top Players and Market Competition in the Skin Microbiome Industry
The skin microbiome market is emerging as a significant area of interest due to growing awareness about the critical role of skin health and innovative skincare technologies. As research advances and consumer preferences shift towards more natural and science-backed products, this market is set to undergo substantial growth. Let's explore the current market size, key players, driving factors, and upcoming trends shaping the skin microbiome industry.
Projected Expansion in the Skin…
Key Strategic Developments and Emerging Changes Shaping the Upadacitinib Market …
The upadacitinib market is poised for significant expansion over the coming years, driven by advances in treatment options and increasing awareness of autoimmune diseases. This report delves into the market's current size, key drivers, major players, and the emerging trends shaping its future trajectory.
Steady Growth Expected in Upadacitinib Market Size Through 2029
The market for upadacitinib is projected to reach $2.54 billion by 2029, growing at a robust compound annual…
Analysis of Key Market Segments Driving the Alzheimer's Disease Diagnostic Marke …
The Alzheimer's disease diagnostic sector is rapidly evolving as advancements in technology and healthcare infrastructure open new possibilities for early detection and personalized treatment. With rising awareness and innovative approaches, this market is poised for significant growth in the coming years. Let's explore the current market size, key drivers, leading companies, and emerging trends that are shaping this critical healthcare field.
Projected Market Size and Growth Trends in Alzheimer's Disease Diagnostics…
More Releases for Primary
Premier Primary Care Medicine Recognized as Top-Rated Primary Care Physician in …
Premier Primary Care Medicine has been recognized as the top-rated primary care physician in Marietta, Georgia. The designation highlights the practice's commitment to accessible, high-quality primary care, same-day and next-day appointments, and an approach centered on long-term patient relationships.
Marietta, GA - September 16, 2025 - Premier Primary Care Medicine [https://www.premierpcmed.com/] has been recognized as the top-rated primary care physician in Marietta, Georgia. The designation highlights the practice's commitment to accessible,…
Direct Primary Care Market
Direct Primary Care Market Worth 80.4 Bn 2031- Exclusive Report by InsightAce Analytic Pvt. Ltd.
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Direct Primary Care Market"- By Type (Clinical Services, Telehealth Services, Laboratory Services, Consultative Services), Care Setting (Office-Based DPC Practices, Home-Based DPC Practices, Telehealth-Only DPC Practices, Hybrid DPC Practices), End Users (Individuals, Employers, Small Businesses, Large Corporations, Insurance Companies (offering DPC as…
Primary Sclerosing Cholangitis Market
Primary Sclerosing Cholangitis (PSC) is a rare, chronic liver disease characterized by inflammation and scarring of the bile ducts, leading to liver damage and, ultimately, liver failure. The disease progresses slowly and often goes unnoticed in its early stages. Although the exact cause of PSC remains unknown, it is commonly associated with other inflammatory bowel diseases, particularly ulcerative colitis. The management of PSC includes symptom control, slowing disease progression, and…
Primary Healthcare Conference 2023
3rd World Congress on Primary Healthcare and Medicare Summit
Mercure Roma West, Viale degli Eroi di Cefalonia, 301, 00128 Rome, Italy
Email primaryhealthcare@pulsusgathering.org
On behalf of the Conference Organizing Committee, we would like to invite all of you for the "3rd Word Congress on Primary Healthcare and Medicare", which is going to be held in Rome, Italy on September 21-23, 2023. Primary Healthcare 2023 focuses on the basic theme "To Manifest the Multimorbidity…
Primary Lithium Battery (Primary Lithium Batteries) Market Key Companies and Ana …
The global lithium primary batteries market size will grow from $2.83 billion in 2022 to $2.9 billion in 2023 at a compound annual growth rate (CAGR) of 2.5%
Global " Primary Lithium Battery (Primary Lithium Batteries) Market" 2022 Reports give a Key study on the industry status of the Primary Lithium Battery (Primary Lithium Batteries) Manufacturer with the specific statistics, meaning, definition, SWOT Analysis, expert opinion, and recent development across…
Primary Prevention of Cancer
Primary prevention of cancer aims to prevent the disease before it ever occurs. More than 4 in 10 cancers as well as cancer deaths are linked to modifiable risk factors that can be altered as part of primary cancer prevention. The modifiable risk factors for primary prevention include:
1. Cigarette smoking: Smoking causes almost all cases of lung cancer and accounts for 30% of all cancer deaths. Prevention strategy for this risk…
